- Home
- TSHA vs FFA Comparison
TSHA vs FFA Comparison
Compare TSHA & FFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- FFA
- Stock Information
- Founded
- TSHA 2019
- FFA 2004
- Country
- TSHA United States
- FFA United States
- Employees
- TSHA N/A
- FFA N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- FFA Investment Managers
- Sector
- TSHA Health Care
- FFA Finance
- Exchange
- TSHA Nasdaq
- FFA Nasdaq
- Market Cap
- TSHA 397.8M
- FFA 400.0M
- IPO Year
- TSHA 2020
- FFA N/A
- Fundamental
- Price
- TSHA $2.71
- FFA $19.73
- Analyst Decision
- TSHA Strong Buy
- FFA
- Analyst Count
- TSHA 7
- FFA 0
- Target Price
- TSHA $7.00
- FFA N/A
- AVG Volume (30 Days)
- TSHA 5.2M
- FFA 26.1K
- Earning Date
- TSHA 05-15-2025
- FFA 01-01-0001
- Dividend Yield
- TSHA N/A
- FFA 6.72%
- EPS Growth
- TSHA N/A
- FFA N/A
- EPS
- TSHA N/A
- FFA N/A
- Revenue
- TSHA $7,224,000.00
- FFA N/A
- Revenue This Year
- TSHA N/A
- FFA N/A
- Revenue Next Year
- TSHA N/A
- FFA N/A
- P/E Ratio
- TSHA N/A
- FFA N/A
- Revenue Growth
- TSHA N/A
- FFA N/A
- 52 Week Low
- TSHA $1.05
- FFA $15.84
- 52 Week High
- TSHA $4.32
- FFA $19.30
- Technical
- Relative Strength Index (RSI)
- TSHA 60.38
- FFA 62.28
- Support Level
- TSHA $2.44
- FFA $19.21
- Resistance Level
- TSHA $2.95
- FFA $19.78
- Average True Range (ATR)
- TSHA 0.25
- FFA 0.18
- MACD
- TSHA -0.02
- FFA -0.00
- Stochastic Oscillator
- TSHA 51.60
- FFA 91.23
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.